AddLife AB
STO:ALIF B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AddLife AB
Gross Profit
AddLife AB
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
AddLife AB
STO:ALIF B
|
Gross Profit
kr4.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Gross Profit
kr780.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
A
|
AroCell AB (publ)
STO:AROC
|
Gross Profit
kr27.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
238%
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Gross Profit
kr1.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
G
|
Genovis AB
STO:GENO
|
Gross Profit
kr115.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
24%
|
CAGR 10-Years
27%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Gross Profit
kr1.2B
|
CAGR 3-Years
33%
|
CAGR 5-Years
28%
|
CAGR 10-Years
17%
|
|
AddLife AB
Glance View
AddLife AB, a prominent player in the life sciences sector, intricately weaves its narrative through a commitment to enhancing healthcare and laboratory services across Europe. Founded in Sweden, the company has established itself as a crucial intermediary, effectively bridging the gap between manufacturers of medical devices and the healthcare institutions that require them. AddLife operates by acquiring and developing niche companies within two core segments: Labtech and Medtech. Through Labtech, it supplies essential equipment, instruments, and consumables for diagnostic and research laboratories. In Medtech, it provides a variety of healthcare logistics, medical products, and services to hospitals and care facilities, enhancing their operational efficiencies. The financial heartbeat of AddLife rests on its adeptness at creating value through strategic acquisitions and organic growth, capitalizing on the increasing demand for innovative healthcare solutions. By continuously expanding its product portfolio and enhancing the capabilities of its subsidiaries, AddLife ensures a diversified revenue stream, mitigating risks associated with dependence on any single product or market. This approach not only fortifies their market position but also fuels their profit margins, as they deftly respond to shifting industry demands and regulatory changes. The company's shared values and decentralized business model promote entrepreneurship within its subsidiaries, fostering an environment where innovation can thrive—ensuring their continued success and substantial contribution to the evolving landscape of healthcare.
See Also
What is AddLife AB's Gross Profit?
Gross Profit
4.1B
SEK
Based on the financial report for Dec 31, 2025, AddLife AB's Gross Profit amounts to 4.1B SEK.
What is AddLife AB's Gross Profit growth rate?
Gross Profit CAGR 5Y
17%
Over the last year, the Gross Profit growth was 4%. The average annual Gross Profit growth rates for AddLife AB have been 6% over the past three years , 17% over the past five years .